124
Participants
Start Date
October 31, 2012
Primary Completion Date
May 31, 2014
Study Completion Date
May 31, 2014
RBP-6000
18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.
Subutex
Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.
Vince and Associates Clinical Research, Overland Park
Lead Sponsor
Indivior Inc.
INDUSTRY